Topic

Partner at Simon-Kucher & Partners, leading its life sciences division in greater China

Articles

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

China’s 2022 NRDL Outlook

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

3 Steps to Navigate Rare Disease Market in China

Jimenez discusses bringing care to diverse and underserved communities.

Q&A With David Jimenez, President of Janssen Immunology

Industry leaders discuss new technologies, research, and investment strategies.

13th Annual PING Conference Highlights Future of UK Pharma Industry

Continent has shed its ‘emerging’ status on world biopharma stage.

Asia’s Rise in The Global Pharma Industry

Group’s ideas to change EU pricing rules draw captive audience.

A Storm in a Brussels Teacup Could Threaten Drug-Pricing Waters

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Q&A With Chitkala Kalidas, vice president and global head, Bayer Oncology Regulatory Affairs and Oncology Sustainability

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare

Steve Scalia is president of Tanner Pharm Group

Bob Mulroy is director and chief executive officer of Partner Therapeutics

John L. McManus is chief business officer of Partner Therapeutics

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Partnering to Respond to a Possible Nuclear Threat

Damien O’Brien is the vice president of life sciences for IDA Ireland, the Irish government’s foreign direct investment agency

Recent growth in pharma makes Ireland an ideal candidate for expansion opportunities.